1. Pink Sheet

Opioid Litigation's Growing Strength: From Snowflakes To Blizzard

 
• By Brenda Sandburg

Infographic examines key opioid events since Purdue's 2007 settlement as legal actions snowball to include disclosures by DEA and wholesalers as well.

Opioid Law Concept 3D Illustration

Eleven years after Purdue Pharma LP pled guilty to marketing OxyContin as less addictive than other pain medicines the legal fallout has only intensified. Manufacturers and distributors are facing an ever-growing barrage of lawsuits and government prosecutors have launched new investigations of their sales and marketing practices. The expected settlements will not just have a financial impact on the firms involved, but may also set a precedent for what public health responsibilities companies are expected to bear.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

EU ‘Can’t Expect Industry To Give Up Proprietary Insights’ Under Health Data & Clinical Trials Regulations

 
• By Eliza Slawther

Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.

How Tumult At US FDA Could Impact Merger and Acquisition Strategy

 
• By Joseph Haas and Nielsen Hobbs

With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.